通过抑制ATPase RUVBL1/2通过抑制胰腺癌中MYC效应器功能的向
Markus Vogt1,2, Nevenka Dudvarski Stankovic1,2, Yiliam Cruz Garcia1,2
1Cancer Systems Biology Group, Chair of Biochemistry and Molecular Biology, Theodor Boveri Institute, University of Würzburg, Würzburg, Germany.
Gut
|May 31, 2024
概括
针对MYCs互动组,研究人员确定了RUVBL1和RUVBL2作为胰腺管道腺癌 (PDAC) 的关键漏洞. 抑制RUVBL1导致小鼠的瘤回归,这表明对MYC驱动癌症的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 对于大多数瘤进展来说,MYC瘤基因至关重要,但它仍然无法被小分子治疗.
- 针对MYC的蛋白相互作用 (互动组) 提供了癌症治疗的替代策略.
- 胰腺管道腺癌 (PDAC) 是一种高度侵袭性的癌症,治疗选择有限.
研究的目的:
- 为了在MYC互动组中确定PDAC治疗的可用药物标.
- 研究MYC结合伙伴在PDAC进展中的作用,在体外和体内.
- 探索RUVBL1和RUVBL2作为MYC驱动癌症的潜在治疗点.
主要方法:
- 建设一个有针对性的shRNA库,用于选MYC绑定合作伙伴.
- 在培养的PDAC细胞和小鼠瘤模型中进行基因选.
- 在体内利用auxin-degron系统对RUVBL1的向蛋白质降解.
主要成果:
- 许多MYC结合伙伴在体外是必不可少的,PDAC细胞在体内是不可缺少的.
- 鉴定出RUVBL1和RUVBL2的ATPases在体内是MYC的关键结合伙伴.
- RUVBL1降解导致PDAC细胞周期停止,小鼠的瘤完全回归,免疫透增加.
- RUVBL1对MYC介导的致癌性和免疫扩散性基因表达至关重要.
结论:
- 瘤微环境显著影响PDAC细胞的依赖性,因此需要进行体外和体内查.
- auxin-degron系统是活生生的小鼠模型中目标验证的可行工具.
- RUVBL1/2复合体代表了一种可用药物的脆弱性,提供了一种新的药物策略,以提高胰腺癌免疫疗法的疗效.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


